Mukka Proteins Presents Q3 & 9M FY26 Investor Presentation, Highlights Growth Strategy
Mukka Proteins released its Q3 & 9M FY26 Investor Presentation. The company, a key player in fish protein, is expanding into insect protein and waste management. It secured a ₹474.89 crore order for leachate treatment and aims for over ₹2,500 crore revenue by FY30. Mukka Proteins is also increasing its stake in EPPL and HMPPL to achieve full ownership.
The announcement is an investor presentation, providing strategic updates and future outlook. While important for stakeholders, it doesn't represent an immediate, direct financial transaction or operational change that would have a high immediate impact.
The investor presentation highlights significant growth strategies, a substantial order win, and future revenue projections, indicating a positive outlook for the company.
Mukka Proteins Limited has released an Investor Presentation for the third quarter and nine months ended December 31, 2025 (Q3 & 9M FY26). The company, a prominent manufacturer and exporter of fishmeal, fish oil, and fish-soluble paste, is evolving into an integrated animal protein and sustainability platform.
The presentation details Mukka Proteins' business overview, highlighting its strengths in fish protein, insect protein, waste management, and frozen seafood. The company aims to leverage its strong global presence across 25+ countries and its market share of 25-30% in fishmeal and fish oil. It also emphasizes its commitment to sustainability, with initiatives like waste-to-value solutions and carbon credit generation.
Key achievements include a ₹474.89 crore order for scientific treatment of legacy leachate by BSWML, a Verra-listed BSF project for carbon credits, and proposed stake increases to wholly own Ento Proteins Pvt. Ltd. (EPPL) and Haris Marine Products Private Limited (HMPPL). The company projects significant revenue growth, targeting over ₹2,500 crore by FY30 from ₹887 crore in FY25.
Financially, the presentation showcases performance updates for Q3 FY26 and 9M FY26, alongside annual financial data for FY23, FY24, and FY25. Mukka Proteins is strategically expanding its operations, including an investment in United Gulf Fishery Products LLC to broaden its Middle East business.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.